Featured

Are we happy, you betcha! We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's approaching $2...

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone -...

Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days...

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we follow, shows a spike in either...

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26 BILLION TRIFECTA...

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever! We're adding Citius Pharma to the Watch...

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class...